Merck Sharp + Dohme Corp.

Ashley Nomland

Shaun R Stauffer

Daniel Vincent Paone

Christopher S Burgey

Anthony T Ginnetti

Diem N Nguyen

Zhengwu James Deng

Craig M Potteiger

John Jin Lim

Ivory D Hills

Carolyn Segerdell

Zhengwu J Deng

John J Lim

The subject invention relates to novel P2X3 receptor antagonists that play a critical role in treating disease states associated with pain, in particular peripheral pain, inflammatory pain, or tissue injury pain that can be treated using a P2X3 receptor subunit modulator.

P2X3 receptor antagonists for treatment of pain

The present invention is directed to fused heterocyclic azaindane carboxamide derivatives which are antagonists of CGRP receptors and useful in the treatment or prevention of diseases in which the CGRP is involved, such as migraine. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which CGRP is involved.

Fused heterocyclic azaindane carboxamide CGRP receptor antagonists

The present invention is directed to spiropiperidine compounds of formula (I) which are inhibitors of the beta-secretase enzyme and that are useful in the treatment of diseases in which the beta-secretase enzyme is involved, such as Alzheimer's disease. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the treatment of such diseases in which the beta-secretase enzyme is involved.

Spiropiperidine beta-secretase inhibitors for the treatment of alzheimer's disease

Growing community of inventors

Boyertown, PA, United States of America

Ashley Nomland